News Releases
- April 29, 2021Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome
- April 15, 2021Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman
- March 17, 2021Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
- March 16, 2021Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients
- March 11, 2021Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage Studies
- March 11, 2021Annovis Bio, Inc. to present at the Q1 Virtual Investor SummitÂ
- March 10, 2021Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury
- March 9, 2021Annovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference
- February 16, 2021Annovis Bio to Present at the BIO CEO & Investor Digital Conference
- February 4, 2021Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top